H.C. Wainwright analyst Douglas Tsao initiated coverage of Evotec with a Buy rating and $12 price target. The company has a platform to drive the discovery and development of novel drugs, Tsao tells investors in a research note. He believes Evotec has established a unique platform that can help clients and partners identify and develop new drugs.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EVO: